08:58 AM EDT, 06/25/2025 (MT Newswires) -- Contineum Therapeutics ( CTNM ) said Wednesday it has completed enrollment of healthy volunteer and progressive multiple sclerosis cohorts for its phase 1b trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 receptor.

The screening and enrollment of idiopathic pulmonary fibrosis patients for the trial is ongoing, the company said.

The trial aims to evaluate the correlation between pharmacokinetics and lysophosphatidic acid 1 receptor occupancy using positron emission tomography imaging in healthy volunteers, idiopathic pulmonary fibrosis patients and progressive multiple sclerosis patients, the company said.

The enrollment of two additional patients to the trial in June has led to a "modest delay" in reporting of the topline data, Contineum Chief Medical Officer Timothy Watkins said, adding that topline data is expected in Q3.

The company's shares were down 7.3% in recent premarket activity on Wednesday.

Price: 4.20, Change: -0.33, Percent Change: -7.28